REDONDO BEACH, CA–(Marketwired – Nov 7, 2016) – SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces an article taking a closer look at AXIM Biotechnologies’ (OTCQB: AXIM) cannabinoid-based clinical trials program. AXIM is advancing their patented controlled-release cannabinoid gum in studies covering a number of indications. […]

by

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the enrollment of the first patients into the STAR 2 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial, an open-label extension trial which allows patients who have completed  the STAR 1 clinical trial […]

by

reader comments 131 Whatever happens November 8, marijuana won. It’s hit an all time high in popularity—60 percent of Americans now support legalization. That handily beats both major-party candidates in favorability. Twenty-five states and Washington, DC have already legalized it for medical use. And come election day, nine states will decide whether to loosen laws […]

by

reader comments 46 Whatever happens November 8, marijuana won. It’s hit an all time high in popularity—60 percent of Americans now support legalization. That handily beats both major-party candidates in favorability. Twenty-five states and Washington, DC have already legalized it for medical use. And come election day, nine states will decide whether to loosen laws […]

by

VANCOUVER, BRITISH COLUMBIA — (Marketwired) — 11/04/16 — Cameo Resources Inc. (TSX VENTURE: CRU)(OTC PINK: SIDNF) (the “Company”) is pleased to announce that the board of directors and the management team have been exploring multiple acquisition opportunities in the medical marijuana and CBD oil industry. The company has been reviewing legislation in those US States […]

by

OTTAWA, ONTARIO–(Marketwired – Nov 2, 2016) – Tetra Bio-Pharma Inc. (“TetraBio” or the “Company“) (CSE:TBP) through its subsidiary, PhytoPain Pharma Inc. (“PPP“), is pleased to announce that it held its Scientific and Clinical Advisory Board (“CAB“) meeting on October 29th. The CAB reviewed the development program of PPP’s inhalation cannabis product PPP001. PPP001 is a […]

by

DEVON, Pa., Nov. 02, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the enrollment of the first patients into the STAR 2 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial, an open-label extension trial which allows […]

by

DEVON, Pa., Nov. 02, 2016 — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the enrollment of the first patients into the STAR 2 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial, an open-label extension trial which allows patients who […]

by

DEVON, Pa., Nov. 02, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the enrollment of the first patients into the STAR 2 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial, an open-label extension trial which allows […]

by

OTTAWA, ONTARIO–(Marketwired – Nov 2, 2016) – Tetra Bio-Pharma Inc. (“TetraBio” or the “Company“) (CSE:TBP) through its subsidiary, PhytoPain Pharma Inc. (“PPP“), is pleased to announce that it held its Scientific and Clinical Advisory Board (“CAB“) meeting on October 29th. The CAB reviewed the development program of PPP’s inhalation cannabis product PPP001. PPP001 is a […]

by

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the enrollment of the first patients into the STAR 2 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial, an open-label extension trial which allows patients who have completed  the STAR 1 clinical trial […]

by

DEVON, Pa., Nov. 02, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the enrollment of the first patients into the STAR 2 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial, an open-label extension trial which allows […]

by